1696

CONTINENTS and REGIONS. HPV and Cervical Cancer in the World: 2007 Report.

1732

cancer and precancer: Implications for screening and vaccination in Japan. Cancer Sci 111(7):

1697

WHO/ICO information Centre on HPV and cervical cancer (HPV Information Centre) 25:

1733

2546-2557.

1698

C1-C26.

1734

67.

1699

56. X. Castellsague, S. d. S., T. Aguado, K.S. Louie, L. Bruni, J. Munoz, M. Diaz, K. Irwin,

1735

HPV16 に対する ELISA 抗体保有状況（2015-2019 年度）．

1700

M. Gacic, O. Beauvais, G. Albero, E. Ferrer, S. Byrne, F.X. Bosch (2007). SECTION II.

1736

https://www.niid.go.jp/niid/ja/y-graphs/667-yosoku-graph.html

1701

COUNTRIES. HPV and Cervical Cancer in the World: 2007 Report. WHO/ICO information

1737

68. Arbyn, M., et al. (2018). Prophylactic vaccination against human papillomaviruses to

1702

Centre on HPV and cervical cancer (HPV Information Centre) 25: C27-C219.

1738

prevent cervical cancer and its precursors. Cochrane Database Syst Rev 5(5): Cd009069.

1703

57. X. Castellsague, S. d. S., T. Aguado, K.S. Louie, L. Bruni, J. Munoz, M. Diaz, K. Irwin,

1739

69. Schwarz, T. F., et al. (2019). A ten-year study of immunogenicity and safety of the AS04-

1704

M. Gacic, O. Beauvais, G. Albero, E. Ferrer, S. Byrne, F.X. Bosch (2007). SECTION III.

1740

HPV-16/18 vaccine in adolescent girls aged 10-14 years. Hum Vaccin Immunother 15(7-8):

1705

METHODS. HPV and Cervical Cancer in the World: 2007 Report. WHO/ICO information

1741

1970-1979.

1706

Centre on HPV and cervical cancer (HPV Information Centre) 25: C221-C230.

1742

70. Schwarz, T. F., et al. (2017). Ten-year immune persistence and safety of the HPV-16/18

1707

58.

de Sanjose, S., et al. (2010). Human papillomavirus genotype attribution in invasive

1743

AS04-adjuvanted vaccine in females vaccinated at 15-55 years of age. Cancer Med 6(11):

1708

cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 11(11): 1048-

1744

2723-2731.

1709

1056. https://www.ncbi.nlm.nih.gov/pubmed/20952254

1745

71.

1710

59. Asato, T., et al. (2004). A large case-control study of cervical cancer risk associated with

1746

Preadolescents and Adolescents After 10 Years. Pediatrics 140(6).

1711

human papillomavirus infection in Japan, by nucleotide sequencing-based genotyping. J

1747

72.

1712

Infect Dis 189(10): 1829-1832. https://www.ncbi.nlm.nih.gov/pubmed/15122519

1748

efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of

1713

60. Onuki, M., et al. (2009). Human papillomavirus infections among Japanese women: age-

1749

three cohorts from randomized trials. BMJ Open 7(8): e015867.

1714

related prevalence and type-specific risk for cervical cancer. Cancer Sci 100(7): 1312-1316.

1750

73.

1715

https://www.ncbi.nlm.nih.gov/pubmed/19432906

1751

adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young

1716

61. Sasagawa, T., et al. (2016). Population-based study for human papillomavirus (HPV)

1752

Japanese women. Hum Vaccin Immunother 10(7): 1781-1794.

1717

infection in young women in Japan: A multicenter study by the Japanese human

1753

74. Yoshikawa, H., et al. (2013). Efficacy of quadrivalent human papillomavirus (types 6, 11,

1718

papillomavirus disease education research survey group (J-HERS). J Med Virol 88(2): 324-

1754

16 and 18) vaccine (GARDASIL) in Japanese women aged 18-26 years. Cancer Sci 104(4):

1719

335. https://www.ncbi.nlm.nih.gov/pubmed/26147986

1755

465-472.

1720

62.

Azuma, Y., et al. (2014). Human papillomavirus genotype distribution in cervical

1756

75.

1721

intraepithelial neoplasia grade 2/3 and invasive cervical cancer in Japanese women. Jpn J Clin

1757

long-term safety of the quadrivalent human papillomavirus vaccine in Japanese women. J

1722

Oncol 44(10): 910-917. https://www.ncbi.nlm.nih.gov/pubmed/25156680

1758

Infect Chemother 25(7): 520-525.

1723

63. Sakamoto, J., et al. (2018). Single type infection of human papillomavirus as a cause for

1759

76. Wheeler, C. M., et al. (2012). Cross-protective efficacy of HPV-16/18 AS04-adjuvanted

1724

high-grade cervical intraepithelial neoplasia and invasive cancer in Japan. Papillomavirus Res

1760

vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types:

1725

6: 46-51. https://www.ncbi.nlm.nih.gov/pubmed/30401640

1761

4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol

1726

64. Kondo, K., et al. (2012). Genotype distribution of human papillomaviruses in Japanese

1762

13(1): 100-110.

1727

women with abnormal cervical cytology. Open Virol J 6: 277-283.

1763

77. Tota, J. E., et al. (2020). Efficacy of the AS04-Adjuvanted HPV16/18 Vaccine: Pooled

1728

65. Torii, Y., et al. (2016). Comparison of methods using paraffin-embedded tissues and

1764

Analysis of the Costa Rica Vaccine and PATRICIA Randomized Controlled Trials. J Natl

1729

exfoliated cervical cells to evaluate human papillomavirus genotype attribution. Cancer Sci

1765

Cancer Inst 112(8): 818-828.

1730

107(10): 1520-1526. https://www.ncbi.nlm.nih.gov/pubmed/27501394

1766

78.

1731

66.

1767

vaccines: a systematic review and meta-analysis. Lancet Infect Dis 12(10): 781-789.

Onuki, M., et al. (2020). Human papillomavirus genotype contribution to cervical

85

国⽴感染症研究所 感染症流⾏予測調査.（2020）.感染症流⾏予測調査事業に基づく

Ferris, D. G., et al. (2017). 4-Valent Human Papillomavirus (4vHPV) Vaccine in
Lehtinen, M., et al. (2017). Ten-year follow-up of human papillomavirus vaccine

Konno, R., et al. (2014). Efficacy of the human papillomavirus (HPV)-16/18 AS04-

Sakamoto, M., et al. (2019). Effectiveness on high-grade cervical abnormalities and

Malagón, T., et al. (2012). Cross-protective efficacy of two human papillomavirus

86